MAPT and Alzheimer disease: IsoLiPro was originally designed and synthesized as a novel organic lithium compound and therapeutic candidate for AD, considering the previously reported multi-targeting benefits of lithium on cognition and AD pathology, including decreased Aβ production and tau phosphorylation (Zhang et al, 2011).